CA3194492A1 - Stat degraders and uses thereof - Google Patents

Stat degraders and uses thereof

Info

Publication number
CA3194492A1
CA3194492A1 CA3194492A CA3194492A CA3194492A1 CA 3194492 A1 CA3194492 A1 CA 3194492A1 CA 3194492 A CA3194492 A CA 3194492A CA 3194492 A CA3194492 A CA 3194492A CA 3194492 A1 CA3194492 A1 CA 3194492A1
Authority
CA
Canada
Prior art keywords
ring
nitrogen
sulfur
oxygen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194492A
Other languages
English (en)
French (fr)
Inventor
Bin Yang
Xiaozhang Zheng
Xiao Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymera Therapeutics Inc
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of CA3194492A1 publication Critical patent/CA3194492A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1027Tetrapeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3194492A 2020-10-07 2021-10-07 Stat degraders and uses thereof Pending CA3194492A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063088787P 2020-10-07 2020-10-07
US63/088,787 2020-10-07
US202063123337P 2020-12-09 2020-12-09
US63/123,337 2020-12-09
PCT/US2021/071762 WO2022077010A1 (en) 2020-10-07 2021-10-07 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
CA3194492A1 true CA3194492A1 (en) 2022-04-14

Family

ID=81126142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194492A Pending CA3194492A1 (en) 2020-10-07 2021-10-07 Stat degraders and uses thereof

Country Status (8)

Country Link
US (1) US20240293423A1 (https=)
EP (1) EP4225303A4 (https=)
JP (1) JP2023545730A (https=)
AU (1) AU2021358130A1 (https=)
CA (1) CA3194492A1 (https=)
IL (1) IL301830A (https=)
MX (1) MX2023003973A (https=)
WO (1) WO2022077010A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
CN115677831B (zh) * 2021-07-22 2026-03-17 杭州和正医药有限公司 拟肽类stat降解药物、组合物及应用
EP4499656A1 (en) * 2022-03-31 2025-02-05 Recludix Pharma, Inc. Stat modulators and uses thereof
WO2024064080A1 (en) * 2022-09-19 2024-03-28 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof
EP4709370A2 (en) * 2023-05-09 2026-03-18 Recludix Pharma, Inc. Stat degraders and uses thereof
EP4712974A2 (en) * 2023-05-15 2026-03-25 Recludix Pharma, Inc. Stat degraders and uses thereof
AU2024334386A1 (en) * 2023-08-30 2026-02-19 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof
WO2025217647A1 (en) * 2024-04-12 2025-10-16 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077589A2 (en) * 2008-12-08 2010-07-08 The Regents Of The University Of Michigan Office Of Technology Transfer Stat3 inhibitors and therapeutic methods using the same
MX2020003190A (es) * 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
CN114269763A (zh) * 2019-03-26 2022-04-01 美国密歇根州立大学试剂中心 Stat3的小分子降解剂

Also Published As

Publication number Publication date
JP2023545730A (ja) 2023-10-31
EP4225303A4 (en) 2025-02-19
AU2021358130A9 (en) 2024-06-27
MX2023003973A (es) 2023-04-24
EP4225303A1 (en) 2023-08-16
IL301830A (en) 2023-06-01
US20240293423A1 (en) 2024-09-05
WO2022077010A1 (en) 2022-04-14
AU2021358130A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
JP7716554B2 (ja) Stat分解剤およびそれらの使用
CA3161878A1 (en) Irak degraders and uses thereof
CA3162502A1 (en) Smarca degraders and uses thereof
WO2020264490A1 (en) Irak degraders and uses thereof
WO2023147594A2 (en) Irak degraders and uses thereof
WO2020251972A1 (en) Smarca degraders and uses thereof
WO2020251971A1 (en) Smarca degraders and uses thereof
CA3170503A1 (en) Stat degraders and uses thereof
EP4076536A1 (en) Irak degraders and uses thereof
CA3194492A1 (en) Stat degraders and uses thereof
WO2021188948A1 (en) Mdm2 degraders and uses thereof
CA3200608A1 (en) Irak degraders and uses thereof
WO2022125804A1 (en) Smarca degraders and uses thereof
WO2023250058A1 (en) Stat degraders and uses thereof
CN116490069A (zh) Stat降解剂和其用途
EA048808B1 (ru) Деградаторы stat и их применение

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240927

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240927

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240927

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118